source
- Osivax’s flu vaccine OVX836 misses primary efficacy goal in phase 2b trialOsivax announced that its influenza A vaccine candidate OVX836 failed to meet the primary efficacy endpoint in a phase 2b trial involving 2,850 healthy adults in Europe. The trial showed a vaccine…
- Experts call for Congress to create a dedicated regulatory framework for AI models used in academic medical centersOn Oct. 15, 2026, several health policy experts voiced support for a new regulatory approach specifically aimed at clinical artificial‑intelligence models that are developed and deployed in academi…